

LIST OF TABLES

1.1 List of Tables

- Table 1: Drivers and Barriers for Non-ART Interventions, 2013
- Table 2: Most Commonly Used Drugs for the Treatment of HIV
- Table 3: ART-Related Side Effects and Comorbidities
- Table 4: Overall Unmet Needs - Current Level of Attainment
- Table 5: HIV Novel R&D Strategies in Early-Stage Development, 2013
- Table 6: Comparison of Novel Therapeutic Classes in Early Development for HIV, 2013
- Table 7: Composition of the ALVAC/AIDS VAX Regimen
- Table 8: Safety and Efficacy Features of ALVAC-HIV+VAXB/E
- Table 9: Product Profile - ALVAC-HIV+VAXB/E
- Table 10: ALVAC-HIV+VAXB/E Advantages and Disadvantages 2013
- Table 11: Product Profile - GeoVax Vaccine
- Table 12: GeoVax Vaccine Advantages and Disadvantages, 2013
- Table 13: Product Profile - AGS-004
- Table 14: AGS-004 Advantages and Disadvantages 2013
- Table 15: Antigens Encoded by pLWXu1
- Table 16: Product Profile - DermaVir Patch
- Table 17: DermaVir Patch Advantages and Disadvantages, 2013
- Table 18: Product Profile - Vacc-4x
- Table 19: Vacc-4x Advantages and Disadvantages, 2013
- Table 20: Latency Reversal Agents under Study
- Table 21: Product Profile - Zolanza
- Table 22: Zolanza Advantages and Disadvantages, 2013
- Table 23: Challenges and Suggested Solutions for Novel R&D Strategies, 2013

1.2 List of Figures

- Figure 1: Timeline of Transition from Treatment to Cure in HIV Treatment and Prevention
- Figure 2: Mapping of Novel Interventions for HIV Cure and Prevention
- Figure 3: Schematic of Complete and Lasting Protection Against HIV Infection
- Figure 4: New Combinatorial Approaches for HIV Eradication
- Figure 5: Number of Ongoing Phase I and Phase II Trials, 2013
- Figure 6: Number of Terminated, Suspended and Withdrawn Phase I and Phase II Trials, 2013
- Figure 7: Schematic Representation of Parallel Clinical Trial Design